Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 48 of 110 Updated Nov 17, 2026

Eloralintide

LY3841136

PHASE 1/2 · AMYLIN RECEPTOR AGONIST (INVESTIGATIONAL)

▓ 34 indexed citations across PubMed (8), ClinicalTrials.gov (22), EuropePMC (4).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

34 citations across 5 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Long-acting amylin receptor agonist

Researched effects

Weight loss; appetite control (Phase 1/2)

Reported efficacy (trial readout)

  • Weight Loss 20%

    Lancet (Phase 2, 48wk, n=263)

    High confidencen=263Phase 22025

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

Trial doses undisclosed

Known concerns

Early-stage trials

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.

    Endocrinology, diabetes & metabolism · 2026 — META-ANALYSES · AUTHORITY 94.5

  2. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

    Diabetes, obesity & metabolism · 2026 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.5

  3. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

    Molecular metabolism · 2025 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.5

  4. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

    Lancet (London, England) · 2025 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.5

  5. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    2026 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.5

  6. Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

    2026 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.5

  7. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    2026 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.5

  8. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    2026 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.5

  9. A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

    2026 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.5

  10. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    2025 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.5

Full citation library

Year distribution

Meta-Analyses

1
  1. 1.

    Kamrul-Hasan ABM, Khalil I, Mahajan K, Dutta D, et al. · Endocrinology, diabetes & metabolism · 2026 · PMID 42175595

    Long-acting amylin-based therapies (ABTs) are emerging anti-obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta-analysis (NMA) framework. We conducted a frequentist random-effects NMA of randomized controlled trials comparing novel ABTs with placebo or active comparators in R. Primary outcome was the percent change in body…

Randomised Controlled Trials

3
  1. 2.

    Briere DA, Qu H, Lansu K, He MM, et al. · Molecular metabolism · 2025 · PMID 41109426

    Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity. In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats and monkeys. A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-a…

  2. 3.

    Billings LK, Hsia S, Bays H, Tidemann-Miller B, et al. · Lancet (London, England) · 2025 · PMID 41207310

    Amylin-based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management. We performed a phase 2, double blind, randomised, placebo-controlled trial with the aim of evaluating the efficacy and safety of a range of doses and dose escalation schemes of once-per-week eloralintide versus placebo in adults with obesity or overweight and had at least one weight-related comorbidity. We enrolled 263 participants…

  3. 4.

    Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, et al. · Diabetes, obesity & metabolism · 2026 · PMID 41559929

    Eloralintide (LY3841136) is a potent, long-acting selective amylin receptor agonist currently under development for the treatment of obesity with once-weekly subcutaneous dosing. This 12-week Phase 1, randomised, placebo-controlled, participant- and investigator-blinded, multiple ascending dose study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic profiles of eloralintide upon once-weekly subcutaneous dosing without dose escalation in participants with obesity or overwe…

Trial Registrations (ClinicalTrials.gov)

22
  1. 5.

    NCT07215559 · Phase 2 · Active Not Recruiting · 2025

    Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2

  2. 6.

    NCT07392190 · Phase 3 · Recruiting · 2026

    Conditions: Overweight, Obesity

  3. 7.

    NCT06916065 · Phase 1 · Completed · 2025

    Conditions: Overweight, Obesity

  4. 8.
  5. 9.

    NCT07426380 · Phase 1 · Completed · 2026

    Conditions: Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic (+3)

  6. 10.

    NCT07353931 · Phase 3 · Recruiting · 2026

    Conditions: Osteoarthritis, Overweight or Obesity

  7. 11.
  8. 12.

    NCT07369011 · Phase 3 · Recruiting · 2026

    Conditions: Sleep Apnea, Obstructive, Obesity, Overweight

  9. 13.

    NCT06916091 · Phase 1 · Completed · 2025

    Conditions: Obesity, Overweight

  10. 14.

    NCT07401862 · Phase 1 · Recruiting · 2026

    Conditions: Hepatic Insufficiency

  11. 15.

    NCT07321886 · Phase 3 · Recruiting · 2026

    Conditions: Obesity, Overweight

  12. 16.

    NCT07282600 · Phase 3 · Recruiting · 2025

    Conditions: Overweight, Obesity

  13. 17.

    NCT07808060 · Phase 1 · Recruiting · 2026

    Conditions: Obesity, Overweight

  14. 18.

    NCT06230523 · Phase 2 · Completed · 2024

    Conditions: Obesity, Overweight

  15. 19.

    NCT07881458 · Phase 3 · Recruiting · 2026

    Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2

  16. 20.

    NCT07765511 · Phase 1 · Not Yet Recruiting · 2026

    Conditions: Obesity, Overweight

  17. 21.

    NCT07935304 · Phase 1 · Not Yet Recruiting · 2026

    Conditions: Healthy

  18. 22.

    NCT07881432 · Phase 3 · Not Yet Recruiting · 2026

    Conditions: Obesity

  19. 23.

    NCT07738614 · Phase 1 · Active Not Recruiting · 2026

    Conditions: Obesity, Overweight

  20. 24.

    NCT07701083 · Phase 1 · Completed · 2026

    Conditions: Healthy Volunteers

  21. 25.

    NCT07665879 · Phase 1 · Recruiting · 2026

    Conditions: Overweight, Obesity

  22. 26.

    NCT07900633 · Phase 3 · Not Yet Recruiting · 2026

    Conditions: Obesity, Overweight, Cardiovascular Diseases (+1)

Reviews

3
  1. 27.

    Bailey CJ, Flatt PR, Conlon JM · Peptides · 2026 · PMID 41747885

    The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weight loss, suppress prandial glucagon release and reduce prandial hyperglycaemia. Recent understanding of the heterodimeric structure of amylin-calcitonin receptor complexes and of amylin structure-function properties has assisted the design of a second…

  2. 28.

    Lempesis IG, Dalamaga M · Metabolism open · 2026 · PMID 41948476

    Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscori…

  3. 29.

    Panou T, Gouveri E, Popovic DS, Papanas N · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 · PMID 42803913

    Type 2 diabetes mellitus (T2DM) and obesity represent two major global health challenges. Amylin-based agonists offer a promising perspective. Three frontrunner agents of this class are increasingly being investigated: zenagamtide, eloralintide and cagrilintide-semaglutide (CagriSema). A search in PubMed/MEDLINE, Scopus and Google Scholar was conducted with the use of appropriate keywords until June 2026 for this narrative review. Zenagamtide (formerly known as amycretin), a unimolecular long-la…

Research Articles

5
  1. 30.

    Mietlicki-Baase EG. · 2026 · PMID 41793055

    Obesity is a disease that is both costly and prevalent, and although the development and use of glucagon-like peptide-1 receptor agonists has dramatically altered the landscape of obesity treatment, there remains a need to identify alternate approaches to reduce body weight. Amylin, a pancreatic hormone, has been viewed as a favorable candidate for novel obesity pharmacotherapies due to its ability to suppress feeding and body weight through its actions in the brain. Although research initially…

  2. 31.

    Bousch C, Bérubé F, Babych M, Ongeri S, Bourgault S. · 2026 · PMID 41898461

    The islet amyloid polypeptide (IAPP) is a peptide hormone playing key biological roles, including glucose homeostasis and regulation of food intake, conferring high therapeutic potential to treat metabolic disorders. Nonetheless, IAPP is mainly known as the major component of the amyloid fibrils observed in the pancreatic islets of patients afflicted with type 2 diabetes, and the accumulation of these insoluble protein deposits correlates closely with the loss of pancreatic β-cells. The inherent…

  3. 32.

    Ryan DH. · 2025 · PMID 40320499

    The development of drugs targeting Nutrient Stimulated Hormone receptors has ushered in a dramatic change in our approach to weight management because of their ability to achieve weight losses of 10%, 20%, even 30% in significant numbers of patients. Additionally, disease modifying properties of these medications are compelling. Indications now include cardiovascular risk reduction, obstructive sleep apnea and diabetes management, and emerging evidence supports efficacy for heart failure and chr…

  4. 33.

    Sidrak WR, Kalra S, Kalhan A. · 2024 · PMID 39676791

    Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain the front-runners in this rapidly evolving landscape of hormone-based AOMs. Two GLP1RAs, namely Liraglutide and Semaglutide, have b…

  5. 34.

    Sigalov A, Frishman WH · Cardiology in review · 2026 · PMID 42745233

    Obesity remains a major modifiable driver of cardiovascular disease. Emerging antiobesity pharmacotherapies demonstrate substantial weight loss alongside improvements in multiple cardiometabolic parameters. This literature review summarizes the early clinical studies of eloralintide, a selective long-acting amylin receptor agonist, and evaluates whether its weight loss and cardiometabolic effects may be relevant to cardiovascular risk reduction. Early clinical studies suggest a potentially disti…

Curated sources on file

24
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.

Continue reading